Stockscreener 앱 받기
3.15
1.07%
-0.04
Agenus Inc 주식(AGEN)의 최신 뉴스
Agenus (AGEN) Q2 2025 Earnings Call Transcript - The Globe and Mail
Colorectal Cancer is Moving in the Wrong Direction – Agenus - Oncodaily
Agenus Strengthens Medical Affairs Infrastructure to Support Growing Authorized Access to Botensilimab–Balstilimab - Oncodaily
Agenus Lands $141M Zydus Partnership to Power BOT+BAL and U.S. Manufacturing Expansion - Oncodaily
Expansion of Global Medical Affairs to Support BOT+BAL Access – Agenus - Oncodaily
Agenus expands medical affairs to support early access to cancer therapy By Investing.com - Investing.com Nigeria
Looking Into Agenus Inc's Recent Short Interest - Benzinga
Agenus expands medical affairs to support early access to cancer therapy - Investing.com
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab - Business Wire
Zydus Gets World’s First Menkes Disease Drug Approval Amid Ardelyx Acquisition Speculation - Citeline News & Insights
Agenus Announces First Stakeholder Webcast of 2026 Focused on BOT+BAL Program - Intellectia AI
Agenus to Host First 2026 Stakeholder Webcast - The AI Journal
Agenus signals expanded access and 2026 plans - Traders Union
Agenus Inc. (NASDAQ:AGEN) Sees Significant Increase in Short Interest - MarketBeat
FY2030 Earnings Estimate for Agenus Issued By HC Wainwright - MarketBeat
Agenus (AGEN) Q1 2025 Earnings Call Transcript - AOL.com
Zydus Completes Agenus Deal, Launches US-Based Biologics CDMO Arm Zylidac Bio - Medical Dialogues
Bear Alert: How sensitive is Agenus Inc to inflationJuly 2025 Sector Moves & Low Risk High Reward Ideas - baoquankhu1.vn
Agenus Forms Major Strategic Collaboration with Zydus Lifesciences - TipRanks
Agenus Announces the Closing of $141M Strategic Collaboration with Zydus Group - Oncodaily
Institution Moves: Will BHRPRD announce a stock splitPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal - Yahoo Finance
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness - 뉴스와이어
Agenus closes strategic collaboration with Zydus Lifesciences By Investing.com - Investing.com Nigeria
Zydus LifeSciences Acquires Biologics Manufacturing Facilities from Agenus - Contract Pharma
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences - BioPharm International
Agenus Falls After $141 Million Zydus Deal Closes - marketscreener.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Zydus Completes Agenus Biologics Facilities Acquisition And Launches U.S. CDMO Unit - Pulse 2.0
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S. - StreetInsider
New Zylidac Bio sites help secure U.S. biologic drug supply chains - Stock Titan
Agenus closes strategic collaboration with Zydus Lifesciences - Investing.com
Zydus Lifesciences Completes Agenus Acquisition, Establishes Zylidac Bio LLC for US Biologics Manufacturing - scanx.trade
Cancer combo shows 42% 2yr survival as $141M immunotherapy deal closes - Stock Titan
Agenus appoints CEO Garo Armen as interim CFO and names new accounting officer - Investing.com Nigeria
Agenus appoints CEO Garo Armen as interim CFO and names new accounting officer By Investing.com - Investing.com South Africa
Agenus Consolidates Financial Leadership With Interim CFO Appointment - TipRanks
Agenus Inc. Appoints Austin Charette as Principal Accounting Officer, Effective January 8, 2026 - marketscreener.com
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas - 뉴스와이어
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Why Agenus Inc. stock is a must watch in 20252025 Geopolitical Influence & Reliable Price Breakout Alerts - Улправда
What risks investors should watch in Agenus Inc. stockEarnings Overview Summary & Daily Stock Trend Reports - Улправда
Is Agenus Inc. stock attractive for income investorsNew Guidance & Low Risk Entry Point Guides - Улправда
Will Agenus Inc. stock sustain high P E ratiosJuly 2025 Setups & Community Verified Swing Trade Signals - Улправда
Agenus amends Ligand agreement, modifies warrant holder rights - TipRanks
How geopolitical tensions affect Agenus Inc. stockMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
2.03%
3.61%
자본화:
|
볼륨(24시간):